IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v17y2020i24p9415-d462652.html
   My bibliography  Save this article

The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China

Author

Listed:
  • Lei Chen

    (School of Health Sciences, Wuhan University, 115# Donghu Road, Wuhan 430071, China
    Global Health Institute, Wuhan University, 115# Donghu Road, Wuhan 430071, China
    These authors contributed equally to this work.)

  • Ying Yang

    (School of Health Sciences, Wuhan University, 115# Donghu Road, Wuhan 430071, China
    Global Health Institute, Wuhan University, 115# Donghu Road, Wuhan 430071, China
    These authors contributed equally to this work.)

  • Mi Luo

    (School of Health Sciences, Wuhan University, 115# Donghu Road, Wuhan 430071, China)

  • Borui Hu

    (School of Health Sciences, Wuhan University, 115# Donghu Road, Wuhan 430071, China)

  • Shicheng Yin

    (School of Health Sciences, Wuhan University, 115# Donghu Road, Wuhan 430071, China)

  • Zongfu Mao

    (School of Health Sciences, Wuhan University, 115# Donghu Road, Wuhan 430071, China
    Global Health Institute, Wuhan University, 115# Donghu Road, Wuhan 430071, China)

Abstract

In 2019, the Chinese government implemented the first round of the National Centralized Drug Procurement (NCDP) pilot (so-called “4 + 7” policy) in mainland China, in which 25 drugs were included. We conducted this study to examine the impacts of NCDP policy on drug utilization and expenditures, and to clarify the main factors contributing to drug expenditure changes. This study used drug purchasing order data from the Centralized Drug Procurement Survey in Shenzhen 2019. Drugs related to the “4 + 7” policy were selected as study samples, including 23 “4 + 7” policy-related varieties and 15 basic alternative drugs. Driving factors for drug expenditures changes were analyzed using A.M. index system analysis (Addis A. & Magrini N.’ method). After the implementation of the NCDP policy, the volume of “4 + 7” policy-related varieties increased by 73.8%, among which winning products jumped by 1638.2% and non-winning products dropped by 70.8%; the expenditures of “4 + 7” policy-related varieties decreased by 36.9%. Structure effects (0.47) and price effects (0.78) negatively contributed to the increase in drug expenditures of “4 + 7” policy-related varieties, while volume effects (1.73) had positive influence. NCDP policy successfully decreased drug expenditures of “4 + 7” policy-related varieties with structure effects playing a leading role. However, total drug expenditures were not effectively controlled due to the increasing use of alternative drugs.

Suggested Citation

  • Lei Chen & Ying Yang & Mi Luo & Borui Hu & Shicheng Yin & Zongfu Mao, 2020. "The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China," IJERPH, MDPI, vol. 17(24), pages 1-11, December.
    • Handle: RePEc:gam:jijerp:v:17:y:2020:i:24:p:9415-:d:462652
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/17/24/9415/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/17/24/9415/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Vandoros, Sotiris & Stargardt, Tom, 2013. "Reforms in the Greek pharmaceutical market during the financial crisis," Health Policy, Elsevier, vol. 109(1), pages 1-6.
    2. Kobayashi, Eriko & Karigome, Hiroshi & Sakurada, Tomoya & Satoh, Nobunori & Ueda, Shiro, 2011. "Patients' attitudes towards generic drug substitution in Japan," Health Policy, Elsevier, vol. 99(1), pages 60-65, January.
    3. Ying Wang & Yulei Zhu & Hang Shi & Xiaoluan Sun & Na Chen & Xin Li, 2019. "The Effect of the Full Coverage of Essential Medicines Policy on Utilization and Accessibility of Primary Healthcare Service for Rural Seniors: A Time Series Study in Qidong, China," IJERPH, MDPI, vol. 16(22), pages 1-14, November.
    4. Lambrelli, Dimitra & O'Donnell, Owen, 2011. "The impotence of price controls: Failed attempts to constrain pharmaceutical expenditures in Greece," Health Policy, Elsevier, vol. 101(2), pages 162-171, July.
    5. Kwon, Hye-Young & Bae, Seungjin & Choi, Sang-eun & Park, Sylvia & Lee, Eui-Kyung & Park, Sungmin & Kim, Jinhyun, 2019. "Easy cuts, easy rebound: Drug expenditures with massive price cuts in Korea," Health Policy, Elsevier, vol. 123(4), pages 388-392.
    6. Yunzhen He & Guanshen Dou & Qiaoyun Huang & Xinyu Zhang & Yingfeng Ye & Mengcen Qian & Xiaohua Ying, 2018. "Does the leading pharmaceutical reform in China really solve the issue of overly expensive healthcare services? Evidence from an empirical study," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-12, January.
    7. Dylst, Pieter & Vulto, Arnold & Simoens, Steven, 2011. "Tendering for outpatient prescription pharmaceuticals: What can be learned from current practices in Europe?," Health Policy, Elsevier, vol. 101(2), pages 146-152, July.
    8. Bonny Parkinson & Catherine Sermet & Fiona Clement & Steffan Crausaz & Brian Godman & Sarah Garner & Moni Choudhury & Sallie-Anne Pearson & Rosalie Viney & Ruth Lopert & Adam Elshaug, 2015. "Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review," PharmacoEconomics, Springer, vol. 33(9), pages 905-924, September.
    9. Lizheng Shi & Heidi Yang & Gang Cheng & Qingyue Meng, 2014. "Time Trends and Determinants of Pharmaceutical Expenditure in China (1990–2009)," PharmacoEconomics, Springer, vol. 32(3), pages 257-264, March.
    10. Kwon, Hye-Young & Hong, Ji-Min & Godman, Brian & Yang, Bong-Min, 2013. "Price cuts and drug spending in South Korea: The case of antihyperlipidemic agents," Health Policy, Elsevier, vol. 112(3), pages 217-226.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Qian Xing & Wenxi Tang & Mingyang Li & Shuailong Li, 2022. "Has the Volume-Based Drug Purchasing Approach Achieved Equilibrium among Various Stakeholders? Evidence from China," IJERPH, MDPI, vol. 19(7), pages 1-22, April.
    2. Yuanyuan Hu & Shouming Chen & Fangjun Qiu & Peien Chen & Shaoxiong Chen, 2021. "Will the Volume-Based Procurement Policy Promote Pharmaceutical Firms’ R&D Investment in China? An Event Study Approach," IJERPH, MDPI, vol. 18(22), pages 1-21, November.
    3. Amarawan Pentrakan & Cheng-Chia Yang & Wing-Keung Wong, 2021. "How Well Does a Sequential Minimal Optimization Model Perform in Predicting Medicine Prices for Procurement System?," IJERPH, MDPI, vol. 18(11), pages 1-17, May.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
    2. Qian Xing & Wenxi Tang & Mingyang Li & Shuailong Li, 2022. "Has the Volume-Based Drug Purchasing Approach Achieved Equilibrium among Various Stakeholders? Evidence from China," IJERPH, MDPI, vol. 19(7), pages 1-22, April.
    3. Sabine Vogler & Valérie Paris & Alessandra Ferrario & Veronika J. Wirtz & Kees Joncheere & Peter Schneider & Hanne Bak Pedersen & Guillaume Dedet & Zaheer-Ud-Din Babar, 2017. "How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 307-321, June.
    4. Moreno Gigi & van Eijndhoven Emma & Benner Jennifer & Sullivan Jeffrey, 2017. "The Long-Term Impact of Price Controls in Medicare Part D," Forum for Health Economics & Policy, De Gruyter, vol. 20(2), pages 1-56, December.
    5. Shu Yan & Lizi Pan & Yan Lu & Juan Chen & Ting Zhang & Dongzi Xu & Zhaolian Ouyang, 2023. "Towards Sustainable Drug Supply in China: A Bibliometric Analysis of Drug Reform Policies," Sustainability, MDPI, vol. 15(13), pages 1-20, June.
    6. Shi, Wunan & Wouters, Olivier J. & Liu, Gordon & Mossialos, Elias & Yang, Xiuyun, 2020. "Association between provincial income levels and drug prices in China over the period 2010–2017," Social Science & Medicine, Elsevier, vol. 263(C).
    7. Kazanis, Ilias, 2013. "Reforming the Greek health system: A role for non-medical, clinical bioscientists," Health Policy, Elsevier, vol. 109(1), pages 46-51.
    8. Tapia Granados, José A. & Rodriguez, Javier M., 2015. "Health, economic crisis, and austerity: A comparison of Greece, Finland and Iceland," Health Policy, Elsevier, vol. 119(7), pages 941-953.
    9. Angelo Claudio Palozzo & Andrea Messori, 2016. "Comment on: “Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review”," PharmacoEconomics, Springer, vol. 34(4), pages 419-420, April.
    10. George Fragkiadakis & Michael Doumpos & Constantin Zopounidis & Christophe Germain, 2016. "Operational and economic efficiency analysis of public hospitals in Greece," Post-Print hal-01414677, HAL.
    11. Takizawa, Osamu & Urushihara, Hisashi & Tanaka, Shiro & Kawakami, Koji, 2015. "Price difference as a predictor of the selection between brand name and generic statins in Japan," Health Policy, Elsevier, vol. 119(5), pages 612-619.
    12. Lins Ferreira, Vinicius & Pereira da Veiga, Cássia Rita & Kudlawicz-Franco, Claudineia & Scalercio, Priscila & Ramires, Yohanna & Pontarolo, Roberto & Carvalho, Denise Maria W. & da Veiga, Claudimar , 2017. "Generic drugs in times of economic crisis: Are there changes in consumer purchase intention?," Journal of Retailing and Consumer Services, Elsevier, vol. 37(C), pages 1-7.
    13. Joo Hanne Poulsen & Lotte Stig Nørgaard & Peter Dieckmann & Marianne Hald Clemmensen, 2021. "Time spent by hospital personnel on drug changes: A time and motion study from an in-and outpatient hospital setting," PLOS ONE, Public Library of Science, vol. 16(2), pages 1-16, February.
    14. Apostolos N. Letsios & George Mavridoglou & Domniki Ladopoulou & Despoina Tsourdini & Nikolaos Dedes & Nikolaos M. Polyzos, 2023. "Exploring the impact of clawback on pharmaceutical expenditure: A case study of public hospitals in Greece," International Journal of Health Planning and Management, Wiley Blackwell, vol. 38(5), pages 1539-1554, September.
    15. Jiae Shin & Dongwoo Ham & Hee Young Paik & Sangah Shin & Hyojee Joung, 2021. "Gender Differences in the Risk of Ischemic Heart Disease According to Healthcare Utilization and Medication Adherence among Newly Treated Korean Hypertensive Patients," IJERPH, MDPI, vol. 18(3), pages 1-13, January.
    16. Livio Garattini & Alessandro Curto & Katelijne Vooren, 2015. "Western European markets for biosimilar and generic drugs: worth differentiating," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(7), pages 683-687, September.
    17. Christensen, Elisabeth & Hirsch, Niels Christian & Andersen, Jonas Valbjørn & Ehlers, Lars Holger, 2022. "The analogue substitution model: Introducing competition in the absence of generic substitution in Danish hospitals," Health Policy, Elsevier, vol. 126(9), pages 844-852.
    18. Skaltsas, Leonora N. & Vasileiou, Konstantinos Z., 2015. "Patients’ perceptions of generic drugs in Greece," Health Policy, Elsevier, vol. 119(11), pages 1406-1414.
    19. Wouters, Olivier J. & Sandberg, Dale M. & Pillay, Anban & Kanavos, Panos G., 2019. "The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period," Social Science & Medicine, Elsevier, vol. 220(C), pages 362-370.
    20. Claude Montmarquette & Stéphanie Boulenger & Joanne Castonguay, 2014. "Les risques liés à la création de PHARMA-QUEBEC," CIRANO Project Reports 2014rp-05, CIRANO.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:17:y:2020:i:24:p:9415-:d:462652. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.